Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Eyepoint Pharmaceuticals Inc (EYPT)

Eyepoint Pharmaceuticals Inc (EYPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
EyePoint Pharmaceuticals: Q3 Earnings Snapshot AP - Wed Nov 5, 6:22AM CST

EyePoint Pharmaceuticals: Q3 Earnings Snapshot

EYPT : 11.58 (+0.61%)
EyePoint Reports Third Quarter 2025 Financial Results and Highlights Recent Corporate Developments GlobeNewswire - Wed Nov 5, 6:00AM CST

– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME...

EYPT : 11.58 (+0.61%)
EyePoint Announces Participation at Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 6:00AM CST

WATERTOWN, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 11.58 (+0.61%)
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025 GlobeNewswire - Wed Oct 29, 6:00AM CDT

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 11.58 (+0.61%)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire - Thu Oct 16, 6:00AM CDT

WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...

EYPT : 11.58 (+0.61%)
EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program Tipranks - Wed Oct 15, 3:46PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. EyePoint...

EYPT : 11.58 (+0.61%)
EyePoint Announces Pricing of Public Offering GlobeNewswire - Tue Oct 14, 9:43PM CDT

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 11.58 (+0.61%)
EyePoint Announces Proposed Public Offering of Common Stock GlobeNewswire - Tue Oct 14, 3:35PM CDT

WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of...

EYPT : 11.58 (+0.61%)
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema GlobeNewswire - Tue Oct 14, 3:01PM CDT

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – –...

EYPT : 11.58 (+0.61%)
Mizuho Securities Sticks to Their Buy Rating for EyePoint Pharmaceuticals (EYPT) Tipranks - Fri Oct 3, 9:02AM CDT

In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on EyePoint Pharmaceuticals, with a price target of $28.00. The company’s shares opened today at $12.92.Elevate...

EYPT : 11.58 (+0.61%)

Barchart Exclusives

The Market Just Pulled Back. Here Is How To Protect Gains And Reset Risk Barchart - Sun Nov 16, 12:45PM CST
Investors panic during pullbacks because they react to emotion instead of structure. This piece shows how to protect gains, reset risk, and turn volatility into opportunity. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot